Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential

Area of Science:

• Molecular Oncology
• Epigenetics
• Gene Regulation

Background:

• Cancer is characterized by molecular heterogeneity, but epigenetic silencing of tumor suppressor genes (TSGs) is a common aberration.
• TSG silencing is an early event in oncogenesis, making TSGs critical targets for cancer therapy.
• Current small molecule strategies aim to restore TSG function, but the underlying molecular mechanisms of silencing are not fully understood.

Purpose of the Study:

• To elucidate the molecular mechanisms driving epigenetic silencing of TSGs in cancer.
• To identify key molecular players involved in the transcriptional repression of TSGs.
• To provide a foundation for developing novel therapeutic strategies targeting TSG reactivation.

Main Methods:

• Review and analysis of proposed molecular mechanisms for TSG silencing.
• Discussion of the strengths and weaknesses of each proposed mechanism.
• Overview of current clinical efforts targeting these epigenetic processes.

Main Results:

• Five primary molecular mechanisms are proposed: 1) ablation of transcription factor binding, 2) overexpression of DNA methyltransferases, 3) disruption of CTCF binding, 4) elevation of EZH2 activity, and 5) aberrant expression of long non-coding RNAs.
• Each mechanism's role in TSG silencing is critically evaluated.
• The study highlights the complexity of epigenetic reprogramming in cancer.

Conclusions:

• Understanding the molecular underpinnings of TSG silencing is crucial for developing effective anti-cancer therapies.
• Targeting these epigenetic mechanisms offers a promising avenue for TSG reactivation and cancer treatment.
• Further research into these pathways will facilitate the development of novel therapeutic interventions.